Kimelman & Baird LLC Sells 440 Shares of Eli Lilly and Company $LLY

Kimelman & Baird LLC reduced its holdings in Eli Lilly and Company (NYSE:LLY) by 1.0% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 44,283 shares of the company’s stock after selling 440 shares during the quarter. Eli Lilly and Company comprises 2.8% of Kimelman & Baird LLC’s holdings, making the stock its 15th largest holding. Kimelman & Baird LLC’s holdings in Eli Lilly and Company were worth $34,520,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Wealth Preservation Advisors LLC bought a new stake in shares of Eli Lilly and Company in the 1st quarter valued at $27,000. Financial Gravity Companies Inc. acquired a new stake in Eli Lilly and Company in the second quarter worth $31,000. Blume Capital Management Inc. increased its stake in Eli Lilly and Company by 46.7% in the second quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock valued at $34,000 after purchasing an additional 14 shares in the last quarter. IMG Wealth Management Inc. acquired a new position in shares of Eli Lilly and Company during the second quarter valued at about $35,000. Finally, TD Capital Management LLC raised its holdings in shares of Eli Lilly and Company by 129.2% during the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock valued at $46,000 after purchasing an additional 31 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Up 0.8%

Shares of NYSE:LLY opened at $1,067.68 on Tuesday. The stock has a market cap of $1.01 trillion, a price-to-earnings ratio of 69.78, a PEG ratio of 1.21 and a beta of 0.43. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,075.72. The business’s 50 day moving average is $862.28 and its 200 day moving average is $790.04.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The business had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company’s quarterly revenue was up 53.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be issued a dividend of $1.50 per share. The ex-dividend date is Friday, November 14th. This represents a $6.00 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s payout ratio is 29.35%.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on LLY. Truist Financial raised their target price on Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the company a “buy” rating in a research note on Wednesday, November 19th. Morgan Stanley raised their price objective on Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the company an “overweight” rating in a research note on Monday. Weiss Ratings restated a “hold (c+)” rating on shares of Eli Lilly and Company in a report on Wednesday, October 8th. Guggenheim reiterated a “buy” rating and issued a $948.00 target price on shares of Eli Lilly and Company in a report on Thursday, October 16th. Finally, Deutsche Bank Aktiengesellschaft reduced their price target on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a research report on Monday, August 11th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $1,047.50.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.